Clinical trials: Ejection Fraction
Heart Failure - NYHA II - IV, Cardiac Fibrosis
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with…
- Conditions
- Heart Failure - NYHA II - IV, Cardiac Fibrosis, Cardiac Remodeling
- Trial name
- NCT06901609
- Testing
- SGLT2 inhibitor (Dapagliflozin 10mg)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Heart Failure, Atherosclerosis
The "ABCDE" Score as a Five-step Vascular Ultrasound Examination in Heart Failure
Heart failure (HF) is a clinical syndrome caused by structural and/or functional cardiac abnormalities, resulting in a reduced cardiac output and/or elevated intra-cardiac pressures at rest or during stress.
- Trial name
- NCT03771209
- Testing
- ultrasound examination
- Where
- Italy
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
This project is an observational study in patients with heart failure with preserved ejection fraction (HFpEF) who are candidates for treatment with weight loss medication to manage obesity or diabetes as part of their standard…
- Trial name
- NCT06930495
- Testing
- Weight loss SOC Treatment with second generation anti-diabetic medications
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Reduced Ejection Fraction
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv…
- Trial name
- METEORIC-HF (NCT03759392)
- Testing
- Omecamtiv Mecarbil
- Where
- 81 sites in United States, Canada and 7 more
- Volunteers
- 276 people
- Sponsor
- Cytokinetics
Transthyretin Amyloidosis, Heart Failure
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF)…
- Conditions
- Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
- Trial name
- TTRinHFpEF (NCT05577819)
- Testing
- 99mTc-pyrophosphate Scintigraphy
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- Massachusetts General Hospital
Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER.
- Trial name
- SMARTER-CMR (NCT07131631)
- Testing
- Cardiac MRI
- Where
- 6 sites in United States, Italy
- Volunteers
- 125 people
- Sponsor
- Minneapolis Heart Institute Foundation
Heart Failure，Congestive, Atrial Fibrillation
The Cardio-share Telemedicine Cross-sector Collaboration Model for Managing Vulnerable Patients With Heart Failure
The goal of this observational study is to explore the potential of implementing a telemedicine-based cross-sector collaboration model to manage patients with frequent admissions with decompensated heart failure.
- Trial name
- ADHFQUAL-BFH (NCT06176131)
- Testing
- Telemedicine-based cross-sector collaboration for patient management
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Pulmonary Hypertension, Systemic Sclerosis
New Orleans Pulmonary Hypertension Biobank
Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure >=25mmHg on right heart catheterization (RHC).
- Conditions
- Pulmonary Hypertension, Systemic Sclerosis, Mixed Connective Tissue Disease, Heart Failure With Normal Ejection Fraction
- Trial name
- NO-PH Biobank (NCT03269630)
- Testing
- No intervention. Biospecimen collection only
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Heart Failure, Heart Failure, Congestive
ANTHEM-HFrEF Pivotal Study
A multi-center randomized controlled clinical trial to evaluate Autonomic Regulation Therapy with the VITARIA system in patients with symptomatic heart failure and reduced ejection fraction.
- Conditions
- Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic
- Trial name
- NCT03425422
- Testing
- VITARIA System
- Where
- 22 sites in United States
- Volunteers
- 533 people
- Sponsor
- LivaNova
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Reduced Ejection Fraction
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety…
- Trial name
- TRACER-HF (NCT03875183)
- Testing
- INL1
- Where
- 13 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Innolife Co., Ltd.
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
- Trial name
- NCT06632483
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- India
- Volunteers
- 604 people
- Sponsor
- Bayer
Heart Failure, Systolic
Robotic-assisted Exercise Training in Heart Failure With Reduced Ejection Fraction
This study will address the challenging task of remobilizing patients with advanced chronic lung or heart failure in a functional New York Heart Association class III-IV by using an externally physically-supported exosuit…
- Trial name
- NCT05278429
- Testing
- Myosuit robotic device
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- German Heart Institute
Left Ventricular Dysfunction, Ventricular Dysfunction
Low Ejection Fraction in Single Lead ECG- Ochsner
The purpose of this research is to prospectively test and validate the single-lead Low EF algorithm in outpatients in order to test the performance of a single-lead ECG based algorithm to identify people with decreased left…
- Conditions
- Left Ventricular Dysfunction, Ventricular Dysfunction, Heart Diseases, Cardiovascular Diseases
- Trial name
- NCT05010642
- Testing
- Use of Eko DUO electronic Stethoscope
- Where
- United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Eko Devices, Inc.
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Use of Advanced Imaging in HFpEF
Heart failure with preserved ejection fraction (HFpEF) causes symptoms of breathlessness and leg swelling. It is associated with significant number of hospital admissions and could lead to the patient's death.
- Trial name
- NCT06905405
- Testing
- Advanced imaging, SGLT-2 inhibitor
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Heart Failure, Systolic, Heart Failure With Preserved Ejection Fraction
Virtual Visits to Optimize Research Trial Offerings to HF Patients
This pilot study seeks to understand if distance health technology with virtual visits hold the key to improving access for patients who wish to partake in clinical trials clearing barriers to enrollment.
- Trial name
- Optimize-HF (NCT04064541)
- Testing
- Virtual Visit
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- The Cleveland Clinic
Arterial Hypertension, Atherosclerosis Occlusive Disease
Gut Microbiota in Chronic Noncommunicable Diseases
It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control…
- Conditions
- Arterial Hypertension, Atherosclerosis Occlusive Disease, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04820556
- Where
- 2 sites in Russia
- Volunteers
- 1,084 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Gallbladder
A Parallel Study Evaluating the Effect of A-F Betafood® on Gallbladder and Liver Function.
Gallstone formation is multifactorial: immutable risk factors include genetics and ethnicity, age and being female, and mutable risk factors include obesity, and metabolic syndrome, diet, rapid weight loss, and other conditions…
- Trial name
- NCT01981343
- Testing
- A-F Betafood
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Heart Failure With Preserved Ejection Fraction, Heart Failure, Congestive
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy.
- Trial name
- PIE-I (NCT01411735)
- Testing
- Enalapril
- Volunteers
- 71 people
- Sponsor
- Wake Forest University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.